Yulia Slavina

Corbus Pharmaceuticals Holdings to unveil new CRB-701 clinical results at ASCO annual meeting

Corbus Pharmaceuticals Holdings to unveil new CRB-701 clinical results at ASCO annual meeting
Corbus to present CRB-701 data

Corbus Pharmaceuticals Holdings, Inc. will host both an in-person and virtual key opinion leader event during the 2026 ASCO annual meeting to share updated results from the Phase 1/2 clinical trial of CRB-701 in 75 patients with head and neck squamous cell carcinoma.

The event aims to provide fresh data and insights into the progress of CRB-701, the company’s experimental treatment for HNSCC. Details on participation in the event and further information about the study are available via the company website.

Corbus previously secured U.S. FDA alignment on the clinical development path for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, advancing registrational planning for the asset (link). The company also confirmed a presentation slot at the 2026 ASCO annual meeting to share new Phase 1/2 data for CRB-701 in both indications (link). These steps mark ongoing progress as Corbus advances its clinical pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.